Cargando…
Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
In this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1–7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1–7) was administered for 60 days (7...
Autores principales: | Marques, Fúlvia D., Melo, Marcos B., Souza, Leandro E., Irigoyen, Maria Claúdia C., Sinisterra, Rúben D., de Sousa, Frederico B., Savergnini, Sílvia Q., Braga, Vinícius B. A., Ferreira, Anderson J., Santos, Robson A. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296310/ https://www.ncbi.nlm.nih.gov/pubmed/22482038 http://dx.doi.org/10.1155/2012/795452 |
Ejemplares similares
-
An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect
por: Fraga-Silva, Rodrigo Araujo, et al.
Publicado: (2011) -
The Novel Mas agonist, CGEN-856S, Attenuates Isoproterenol-Induced Cardiac Remodeling and Myocardial Infarction Injury in Rats
por: Savergnini, Sílvia Q., et al.
Publicado: (2013) -
Oral Formulation of Angiotensin-(1-7) Promotes Therapeutic Actions in a Model of Eosinophilic and Neutrophilic Asthma
por: Magalhães, Giselle Santos, et al.
Publicado: (2021) -
Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction
por: Carvalho, Juliana L, et al.
Publicado: (2013) -
Treatment with angiotensin II in COVID-19 patients may not be beneficial
por: Rysz, Susanne, et al.
Publicado: (2020)